Lotronex Advisory Committee Will Discuss Program For Ischemic Colitis Risk

A risk management program to track postmarketing incidences of ischemic colitis with Glaxo Wellcome's Lotronex will be discussed at the June 27 meeting of FDA's Gastrointestinal Drugs Advisory Committee.